| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8733715 | Critical Reviews in Oncology/Hematology | 2018 | 17 Pages |
Abstract
the review shows the rapid drifting in the management of ALK+ NSCLC patients and the importance of fully understanding and acknowledging the role of the resistance mutation, primary or acquired. We strongly advocate a comprehensive genomic approach in the management of ALK+ NSCLC patients who develop resistance mutations that are still targetable by a different ALK inhibitor.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Hematology
Authors
Alfredo Addeo, Fabrizio Tabbò, Tim Robinson, Lucio Buffoni, Silvia Novello,